Products – Bone Biologics

NELL-1 Product Pipeline

NELL-1 is our groundbreaking platform technology that has shown promise in improving bone healing and clinical outcomes in a range of orthopedic applications.

Platform Technology

Spine

Spine fusion is a surgical procedure to join or fuse two or more vertebrae in the back to relieve nerve pain.

The global spine market is $10 billion and growing by low single digits annually. Approximately 30% of the U.S. population reports back pain, of which 2% receive a diagnosis, and 65% get treatment.to relieve nerve pain.

Current treatments often have suboptimal results among those with deemed hard healers resulting in prolonged pain and disability.to relieve nerve pain.

NELL-1’s ability to promote precise bone formation and accelerate healing makes it a promising tool to enhance spine fusion success rates.

Trauma

Orthopedic trauma is an injury to the musculoskeletal system, which includes bones, joints, muscles, tendons, ligaments and cartilage. It is usually caused by an external force like a fall, car accident or sports injury, and also can be age related.

The global trauma market is approximately $8 billion annually. Orthobiologics are typically used for the treatment of trauma involving non-unions, delayed unions or bone defects.

NELL-1 is a promising solution for improving recovery times and enhancing bone healing in critical areas like the pelvis or long bones.

Osteoporosis

Osteoporosis occurs when the creation of new bone does not keep up with the loss of old bone. About 50% of women and 25% of men age 50+ will experienc an osteoporosis-related fracture.

Osteoporosis drugs fall into two classes: anti-resorptive drugs, which slow down bone loss; and anabolic drugs, which improve bone formation. Together they represent a $11 billion global market.

NELL-1’s ability to stimulate bone growth has promise as a breakthrough solution in treating osteoporosis by enhancing bone density and reducing fracture risk.

How Does NELL-1 Work

NELL-1 (Neural EGF-like protein 1) is a naturally occurring protein that plays a crucial role in bone formation. As a growth factor, NELL-1 directly stimulates bone formation and enhances bone quality by regulating key cellular pathways involved in bone repair. NELL-1’s mechanism of action includes its ability to guide bone formation at the right time and place, offering significant advantages over current therapies.

Activation of Bone-Regenerating Pathways	Precise Bone Formation	Inhibition of Adipogenesis	Enhanced Safety Profile
NELL-1 binds to specific receptors on mesenchymal stem cells and osteoblasts, triggering a cascade of signaling events that promote bone formation. NELL-1 enhances the expression of osteogenic markers such as Runx2 and osteocalcin, both essential for bone cell differentiation and bone matrix deposition.	Unlike traditional growth factors including recombinant bone morphogenetic protein, NELL-1 operates later in the bone formation pathway, ensuring bone growth only at the site of injury; this reduces the risk of inflammation or unwanted tissue formation.	NELL-1 inhibits the differentiation of mesenchymal stem cells into fat cells (adipogenesis), directing them to form bone, a unique property that enhances its efficacy in bone regeneration.	NELL-1’s late-stage action in the bone healing cascade means it avoids early-stage inflammation and reduces the likelihood of complications seen with other bone growth factors.

Activation of Bone-Regenerating Pathways

Precise Bone Formation

Inhibition of Adipogenesis

Enhanced Safety Profile

NELL-1 binds to specific receptors on mesenchymal stem cells and osteoblasts, triggering a cascade of signaling events that promote bone formation.

NELL-1 enhances the expression of osteogenic markers such as Runx2 and osteocalcin, both essential for bone cell differentiation and bone matrix deposition.

Unlike traditional growth factors including recombinant bone morphogenetic protein, NELL-1 operates later in the bone formation pathway, ensuring bone growth only at the site of injury; this reduces the risk of inflammation or unwanted tissue formation.

NELL-1 inhibits the differentiation of mesenchymal stem cells into fat cells (adipogenesis), directing them to form bone, a unique property that enhances its efficacy in bone regeneration.

NELL-1’s late-stage action in the bone healing cascade means it avoids early-stage inflammation and reduces the likelihood of complications seen with other bone growth factors.

Activation of Bone-Regenerating Pathways	NELL-1 binds to specific receptors on mesenchymal stem cells and osteoblasts, triggering a cascade of signaling events that promote bone formation. NELL-1 enhances the expression of osteogenic markers such as Runx2 and osteocalcin, both essential for bone cell differentiation and bone matrix deposition.
Precise Bone Formation	Unlike traditional growth factors including recombinant bone morphogenetic protein, NELL-1 operates later in the bone formation pathway, ensuring bone growth only at the site of injury; this reduces the risk of inflammation or unwanted tissue formation.
Inhibition of Adipogenesis	NELL-1 inhibits the differentiation of mesenchymal stem cells into fat cells (adipogenesis), directing them to form bone, a unique property that enhances its efficacy in bone regeneration.
Enhanced Safety Profile	NELL-1’s late-stage action in the bone healing cascade means it avoids early-stage inflammation and reduces the likelihood of complications seen with other bone growth factors.